603456 九洲药业
已收盘 04-15 15:00:00
资讯
新帖
简况
九洲药业(603456.SH)：磺胺二甲氧嘧啶原料药获得CEP认证证书
智通财经 · 03-25
九洲药业(603456.SH)：磺胺二甲氧嘧啶原料药获得CEP认证证书
3月23日九洲药业跌5.80%，富国双债增强债券A基金重仓该股
证券之星 · 03-23
3月23日九洲药业跌5.80%，富国双债增强债券A基金重仓该股
每周股票复盘：九洲药业（603456）子公司获新药注册证
证券之星 · 03-22
每周股票复盘：九洲药业（603456）子公司获新药注册证
九洲药业(603456.SH)子公司取得氢溴酸伏硫西汀片药品注册证书
智通财经 · 03-16
九洲药业(603456.SH)子公司取得氢溴酸伏硫西汀片药品注册证书
九洲药业（603456）披露使用部分闲置募集资金进行现金管理到期赎回的公告，2月24日股价上涨0.57%
证券之星 · 02-24
九洲药业（603456）披露使用部分闲置募集资金进行现金管理到期赎回的公告，2月24日股价上涨0.57%
每周股票复盘：九洲药业（603456）闲置募资管理进展更新
证券之星 · 02-15
每周股票复盘：九洲药业（603456）闲置募资管理进展更新
每周股票复盘：九洲药业（603456）使用1000万元闲置募集资金购买定期存款
证券之星 · 02-08
每周股票复盘：九洲药业（603456）使用1000万元闲置募集资金购买定期存款
九洲药业（603456）披露关于开立募集资金现金管理产品专用结算账户及使用闲置募集资金进行现金管理的进展公告，2月6日股价下跌0.22%
证券之星 · 02-06
九洲药业（603456）披露关于开立募集资金现金管理产品专用结算账户及使用闲置募集资金进行现金管理的进展公告，2月6日股价下跌0.22%
每周股票复盘：九洲药业（603456）子公司完成创投基金备案
证券之星 · 02-01
每周股票复盘：九洲药业（603456）子公司完成创投基金备案
九洲药业（603456）披露关于使用闲置募集资金进行现金管理到期赎回并继续进行现金管理的公告，1月28日股价下跌1.82%
证券之星 · 01-28
九洲药业（603456）披露关于使用闲置募集资金进行现金管理到期赎回并继续进行现金管理的公告，1月28日股价下跌1.82%
每周股票复盘：九洲药业（603456）获枸橼酸坦度螺酮原料药上市批准
证券之星 · 01-18
每周股票复盘：九洲药业（603456）获枸橼酸坦度螺酮原料药上市批准
九洲药业（603456）披露收到化学原料药上市申请批准通知书，1月16日股价下跌0.51%
证券之星 · 01-16
九洲药业（603456）披露收到化学原料药上市申请批准通知书，1月16日股价下跌0.51%
九洲药业最新公告：收到化学原料药上市申请批准通知书
证券之星 · 01-16
九洲药业最新公告：收到化学原料药上市申请批准通知书
每周股票复盘：九洲药业（603456）瑞博制药获高新认定享税收优惠
证券之星 · 01-11
每周股票复盘：九洲药业（603456）瑞博制药获高新认定享税收优惠
每周股票复盘：九洲药业（603456）子公司投1000万参设医药基金
证券之星 · 2025-12-28
每周股票复盘：九洲药业（603456）子公司投1000万参设医药基金
九洲药业(603456.SH)子公司拟参与投资嘉兴隆峰创业投资合伙企业(有限合伙)
智通财经网 · 2025-12-22
九洲药业(603456.SH)子公司拟参与投资嘉兴隆峰创业投资合伙企业(有限合伙)
九洲药业（603456）披露部分募投项目延期公告，12月9日股价下跌0.71%
证券之星 · 2025-12-09
九洲药业（603456）披露部分募投项目延期公告，12月9日股价下跌0.71%
九洲药业(603456.SH)：西格列汀二甲双胍缓释片ANDA通过美国FDA上市许可批准
智通财经 · 2025-11-27
九洲药业(603456.SH)：西格列汀二甲双胍缓释片ANDA通过美国FDA上市许可批准
九洲药业（603456）披露收到化学原料药上市申请批准通知书，11月24日股价上涨1.56%
证券之星 · 2025-11-24
九洲药业（603456）披露收到化学原料药上市申请批准通知书，11月24日股价上涨1.56%
九洲药业(603456.SH)：甲苯磺酸艾多沙班化学原料药上市申请获批准
智通财经 · 2025-11-24
九洲药业(603456.SH)：甲苯磺酸艾多沙班化学原料药上市申请获批准
加载更多
公司概况
公司名称：
浙江九洲药业股份有限公司
所属行业：
医药制造业
上市日期：
2014-10-10
主营业务：
浙江九洲药业股份有限公司的主营业务是为全球制药公司、生物科技公司、科研机构等提供一站式的医药定制研发和生产（CDMO）服务。公司的主要产品是抗感染类、中枢神经类药物、非甾体类药物、降血糖类药等。公司荣获2025中国医药CDMO企业20强、2024年度中国医药工业主营业务收入前100位企业、2024年EcoVadis企业社会责任评级“金牌”认证、全球优选合作伙伴奖、ESG责任企业奖等多项荣誉。
发行价格：
15.43
{"stockData":{"symbol":"603456","market":"SH","secType":"STK","nameCN":"九洲药业","latestPrice":17.47,"timestamp":1776236400000,"preClose":17.26,"halted":0,"volume":17914183,"delay":0,"changeRate":0.0122,"floatShares":889000000,"shares":889000000,"eps":0.8128,"marketStatus":"已收盘","change":0.21,"latestTime":"04-15 15:00:00","open":17.57,"high":17.79,"low":17.2,"amount":313000000,"amplitude":0.0342,"askPrice":17.47,"askSize":77,"bidPrice":17.46,"bidSize":64,"shortable":0,"etf":0,"ttmEps":0.8128,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776303000000},"marketStatusCode":5,"adr":0,"adjPreClose":17.26,"symbolType":"stock","openAndCloseTimeList":[[1776216600000,1776223800000],[1776229200000,1776236400000]],"highLimit":18.99,"lowLimit":15.53,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":889446028,"isCdr":false,"pbRate":1.77,"roa":"--","peRate":21.493602,"roe":"8.57%","epsLYR":0.68,"committee":-0.607504,"marketValue":15539000000,"turnoverRate":0.0201,"status":0,"floatMarketCap":15539000000},"requestUrl":"/m/hq/s/603456","defaultTab":"news","newsList":[{"id":"2622028072","title":"九洲药业(603456.SH)：磺胺二甲氧嘧啶原料药获得CEP认证证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2622028072","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622028072?lang=zh_cn&edition=full","pubTime":"2026-03-25 15:39","pubTimestamp":1774424374,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九洲药业(603456.SH)发布公告，近日，公司收到欧洲药品质量管理局(简称“EDQM”)签发的磺胺二甲氧嘧啶原料药欧洲药典适用性认证证书。磺胺二甲氧嘧啶属于磺胺类抗生素，主要用于治疗畜禽由敏感菌引起的多种感染。本次公司磺胺二甲氧嘧啶原料药获得CEP认证证书，显示欧洲规范市场对该原料药质量的认可和肯定，标志此产品具备以原料药形式进入欧盟及承认CEP证书的其他市场的资质，为公司进一步拓展国际市场带来积极的影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603456","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621775796","title":"3月23日九洲药业跌5.80%，富国双债增强债券A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2621775796","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621775796?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:28","pubTimestamp":1774254523,"startTime":"0","endTime":"0","summary":"证券之星消息，3月23日九洲药业跌5.80%创60日新低，收盘报15.28元，换手率1.94%，成交量17.3万手，成交额2.69亿元。重仓九洲药业的前十大公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共14家，其中持有数量最多的公募基金为富国基金的富国双债增强债券A。该公募基金现任基金经理为俞晓斌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300025023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603456","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621796080","title":"每周股票复盘：九洲药业（603456）子公司获新药注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2621796080","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621796080?lang=zh_cn&edition=full","pubTime":"2026-03-22 02:25","pubTimestamp":1774117514,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，九洲药业报收于16.22元，较上周的16.82元下跌3.57%。本周，九洲药业3月17日盘中最高价报17.12元。九洲药业当前最新总市值144.27亿元，在医疗服务板块市值排名11/51，在两市A股市值排名1394/5190。该药品用于成人重度抑郁障碍治疗，注册分类为化学药品4类。此次获批将进一步丰富公司产品管线，提升市场竞争力，但短期内不会对公司业绩产生重大影响。药品生产和销售受市场环境、政策等因素影响，存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","603456","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619430292","title":"九洲药业(603456.SH)子公司取得氢溴酸伏硫西汀片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2619430292","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619430292?lang=zh_cn&edition=full","pubTime":"2026-03-16 15:52","pubTimestamp":1773647535,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 九洲药业 发布公告，近日，公司全资子公司九洲生物医药(台州)有限公司收到国家药品监督管理局核准签发的氢溴酸伏硫西汀片的《药品注册证书》。氢溴酸伏硫西汀片主要用于成人重度抑郁障碍的治疗。根据公开数据显示，氢溴酸伏硫西汀片2024年国内医疗市场和零售市场销售总额(终端价)为2.14亿元人民币。截至目前，公司已在氢溴酸伏硫西汀片累计研发投入约为人民币1,262万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414274.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"九洲药业(603456.SH)子公司取得氢溴酸伏硫西汀片药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","603456","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613790794","title":"九洲药业（603456）披露使用部分闲置募集资金进行现金管理到期赎回的公告，2月24日股价上涨0.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613790794","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613790794?lang=zh_cn&edition=full","pubTime":"2026-02-24 19:04","pubTimestamp":1771931046,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，九洲药业报收于17.65元，较前一交易日上涨0.57%，最新总市值为156.99亿元。近日，浙江九洲药业股份有限公司发布《关于使用部分闲置募集资金进行现金管理到期赎回的公告》。公告显示，公司子公司九洲药业（台州）此前使用闲置募集资金4,000万元购买的中国工商银行现金管理产品已到期赎回，本金及收益均已到账并归还至募集资金专户。目前使用的现金管理额度为79,000万元，未超过董事会审批的10亿元额度。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400038002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","603456","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611435911","title":"每周股票复盘：九洲药业（603456）闲置募资管理进展更新","url":"https://stock-news.laohu8.com/highlight/detail?id=2611435911","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611435911?lang=zh_cn&edition=full","pubTime":"2026-02-15 01:15","pubTimestamp":1771089313,"startTime":"0","endTime":"0","summary":"截至2026年2月13日收盘，九洲药业报收于17.55元，较上周的17.88元下跌1.85%。本周，九洲药业2月12日盘中最高价报18.25元。本周关注点公司公告汇总：九洲药业子公司赎回4,000万元闲置募集资金理财，本金及收益已到账。公司公告汇总浙江九洲药业股份有限公司于2026年2月14日发布公告，披露子公司九洲药业（台州）此前使用闲置募集资金4,000万元购买的中国工商银行现金管理产品已到期赎回，本金及收益均已到账并归还至募集资金专户。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021500000148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","603456","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609526875","title":"每周股票复盘：九洲药业（603456）使用1000万元闲置募集资金购买定期存款","url":"https://stock-news.laohu8.com/highlight/detail?id=2609526875","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609526875?lang=zh_cn&edition=full","pubTime":"2026-02-08 02:40","pubTimestamp":1770489624,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，九洲药业报收于17.88元，较上周的18.24元下跌1.97%。本周，九洲药业2月2日盘中最高价报18.24元。九洲药业当前最新总市值159.03亿元，在医疗服务板块市值排名11/51，在两市A股市值排名1305/5186。本周关注点公司公告汇总：九洲药业全资子公司使用1,000万元闲置募集资金购买3个月定期存款。公司已对资金管理制定了相应风险控制措施。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603456","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609594855","title":"九洲药业（603456）披露关于开立募集资金现金管理产品专用结算账户及使用闲置募集资金进行现金管理的进展公告，2月6日股价下跌0.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609594855","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609594855?lang=zh_cn&edition=full","pubTime":"2026-02-06 22:20","pubTimestamp":1770387633,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，九洲药业报收于17.88元，较前一交易日下跌0.22%，最新总市值为159.03亿元。近日，浙江九洲药业股份有限公司发布《关于开立募集资金现金管理产品专用结算账户及使用闲置募集资金进行现金管理的进展公告》。公告显示，公司全资子公司瑞华（中山）制药有限公司在中国农业银行台州椒江支行开立募集资金现金管理子账户，并使用1,000万元闲置募集资金购买期限为3个月的定期存款。公司已对资金管理制定了相应风险控制措施。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600041038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603456","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608077540","title":"每周股票复盘：九洲药业（603456）子公司完成创投基金备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2608077540","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608077540?lang=zh_cn&edition=full","pubTime":"2026-02-01 02:46","pubTimestamp":1769885172,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，九洲药业报收于18.24元，较上周的19.3元下跌5.49%。本周，九洲药业1月26日盘中最高价报19.4元。本周关注点公司公告汇总：全资子公司参与投资的嘉兴隆峰创业投资合伙企业完成备案，认缴出资1,000万元。该合伙企业已在中国证券投资基金业协会完成备案，备案编码为SBCH85，备案日期为2026年1月26日。浙江九洲药业股份有限公司使用闲置募集资金3,000万元购买农业银行常熟经济开发区支行的大额存单，期限6个月，预计年化收益率1.10%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","603456"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606712721","title":"九洲药业（603456）披露关于使用闲置募集资金进行现金管理到期赎回并继续进行现金管理的公告，1月28日股价下跌1.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606712721","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606712721?lang=zh_cn&edition=full","pubTime":"2026-01-28 22:14","pubTimestamp":1769609661,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘，九洲药业报收于18.37元，较前一交易日下跌1.82%，最新总市值为163.39亿元。近日，浙江九洲药业股份有限公司发布《关于使用闲置募集资金进行现金管理到期赎回并继续进行现金管理的公告》。公告显示，公司使用闲置募集资金3,000万元购买农业银行常熟经济开发区支行的大额存单，期限6个月，预计年化收益率1.10%。目前公司使用闲置募集资金进行现金管理的尚未收回本金金额为82,000万元，累计收益738.15万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800042649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603456","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604928226","title":"每周股票复盘：九洲药业（603456）获枸橼酸坦度螺酮原料药上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2604928226","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604928226?lang=zh_cn&edition=full","pubTime":"2026-01-18 01:54","pubTimestamp":1768672450,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，九洲药业报收于19.64元，较上周的19.44元上涨1.03%。本周，九洲药业1月14日盘中最高价报20.2元。九洲药业当前最新总市值174.69亿元，在医疗服务板块市值排名12/51，在两市A股市值排名1204/5183。本周关注点公司公告汇总：九洲药业收到枸橼酸坦度螺酮化学原料药上市申请批准通知书。目前该原料药在CDE原辅包登记平台状态为“A”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","603456","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603755991","title":"九洲药业（603456）披露收到化学原料药上市申请批准通知书，1月16日股价下跌0.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603755991","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603755991?lang=zh_cn&edition=full","pubTime":"2026-01-16 22:14","pubTimestamp":1768572860,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，九洲药业报收于19.64元，较前一交易日下跌0.51%，最新总市值为174.69亿元。该股当日开盘19.7元，最高19.82元，最低19.45元，成交额达3.26亿元，换手率为1.87%。近日，浙江九洲药业股份有限公司发布公告称，公司收到国家药品监督管理局颁发的关于枸橼酸坦度螺酮的《化学原料药上市申请批准通知书》，批准该原料药上市。公司已于2024年7月提交申请，累计研发投入约623万元。目前该原料药在CDE原辅包登记平台状态为“A”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600040930.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603456","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603961367","title":"九洲药业最新公告：收到化学原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2603961367","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603961367?lang=zh_cn&edition=full","pubTime":"2026-01-16 17:21","pubTimestamp":1768555318,"startTime":"0","endTime":"0","summary":"九洲药业(603456.SH)公告称，公司收到国家药品监督管理局颁发的关于枸橼酸坦度螺酮的《化学原料药上市申请批准通知书》。该原料药主要用于各种神经症所致的焦虑状态，如广泛性焦虑症；原发性高血压、消化性溃疡等躯体疾病伴发的焦虑状态。公司于2024年7月向国家药品监督管理局药品审评中心提交该原料药的上市申请，并于近日取得国家药监局下发的《化学原料药上市申请批准通知书》。该事项短期内不会对公司业绩产生重大影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600027968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","603456"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602535663","title":"每周股票复盘：九洲药业（603456）瑞博制药获高新认定享税收优惠","url":"https://stock-news.laohu8.com/highlight/detail?id=2602535663","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602535663?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:40","pubTimestamp":1768070422,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，九洲药业报收于19.44元，较上周的17.9元上涨8.6%。本周，九洲药业1月9日盘中最高价报19.48元。本周关注点公司公告汇总：全资子公司瑞博制药获高新技术企业认定，2025-2027年按15%税率缴所得税公司公告汇总浙江九洲药业股份有限公司全资子公司浙江瑞博制药有限公司通过高新技术企业认定，证书编号GR202533010708，发证日期2025年12月19日，有效期三年。2025年至2027年期间，瑞博制药将享受15%的企业所得税优惠税率。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000674.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603456","BK1574","BK0239","01477","BK1191","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2594624141","title":"每周股票复盘：九洲药业（603456）子公司投1000万参设医药基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2594624141","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594624141?lang=zh_cn&edition=full","pubTime":"2025-12-28 01:50","pubTimestamp":1766857815,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，九洲药业报收于18.14元，较上周的18.29元下跌0.82%。本周，九洲药业12月25日盘中最高价报18.45元。本周关注点公司公告汇总：九洲药业子公司认缴1000万元参与投资嘉兴隆峰创投，布局医药领域。公司公告汇总浙江九洲药业股份有限公司全资子公司浙江宏洲股权投资有限公司参与投资嘉兴隆峰创业投资合伙企业，认缴出资1,000万元，占总认缴出资额的12.987%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603456","BK0070","160635","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593251100","title":"九洲药业(603456.SH)子公司拟参与投资嘉兴隆峰创业投资合伙企业(有限合伙)","url":"https://stock-news.laohu8.com/highlight/detail?id=2593251100","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593251100?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:37","pubTimestamp":1766392677,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九洲药业 发布公告，公司全资子公司宏洲投资拟参与投资嘉兴隆峰创业投资合伙企业。合伙企业认缴出资总额为7700万元，宏洲投资将作为有限合伙人以自有资金认缴出资额为1000万元，占合伙企业认缴出资总额的12.987%。合伙企业投资方向：主要投资于新药研发、医疗器械研发项目等医药相关领域，主要包括优质的新兴医疗企业，包括但不限于新药、创新药、医疗器械、医疗服务、诊断、生物技术、医药外包研发企业等。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0070","603456","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590344254","title":"九洲药业（603456）披露部分募投项目延期公告，12月9日股价下跌0.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590344254","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590344254?lang=zh_cn&edition=full","pubTime":"2025-12-09 22:11","pubTimestamp":1765289486,"startTime":"0","endTime":"0","summary":"截至2025年12月9日收盘，九洲药业报收于18.3元，较前一交易日下跌0.71%，最新总市值为162.77亿元。该股当日开盘18.39元，最高18.75元，最低18.25元，成交额达2.24亿元，换手率为1.36%。截至2025年6月30日，该项目募集资金承诺投资总额28,000.00万元，实际投入23,118.49万元，投入进度82.57%。公告称，延期主要因工程结算进度等不可控因素，项目延期不涉及实施主体、方式、投资总额及内容变更，未改变募集资金用途。保荐机构华泰联合证券对该事项无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900040284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","603456"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586669210","title":"九洲药业(603456.SH)：西格列汀二甲双胍缓释片ANDA通过美国FDA上市许可批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2586669210","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586669210?lang=zh_cn&edition=full","pubTime":"2025-11-27 16:04","pubTimestamp":1764230687,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九洲药业 发布公告，近日，公司控股子公司浙江九洲生物医药有限公司向美国食品药品监督管理局提交的西格列汀二甲双胍缓释片简略新药申请的已获得美国FDA的暂时批准。西格列汀二甲双胍缓释片主要用于经二甲双胍单药治疗血糖仍控制不佳或正在接受二者联合治疗的2型糖尿病患者。西格列汀二甲双胍缓释片的原研药为JanumetXR，由默沙东公司研发，于2012年2月在美国上市。根据公开数据显示，2024年该药品美国市场销售额约11亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"九洲药业(603456.SH)：西格列汀二甲双胍缓释片ANDA通过美国FDA上市许可批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0070","603456"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585604674","title":"九洲药业（603456）披露收到化学原料药上市申请批准通知书，11月24日股价上涨1.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585604674","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585604674?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:13","pubTimestamp":1763993603,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘，九洲药业报收于18.91元，较前一交易日上涨1.56%，最新总市值为168.19亿元。该股当日开盘18.75元，最高19.06元，最低18.61元，成交额达3.34亿元，换手率为1.99%。公司近日发布公告称，浙江九洲药业股份有限公司近日收到国家药品监督管理局颁发的关于甲苯磺酸艾多沙班的《化学原料药上市申请批准通知书》，批准该原料药上市申请。该原料药主要用于预防非瓣膜性房颤患者的卒中及全身性栓塞，以及治疗或预防深静脉血栓和肺栓塞。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400035274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","603456"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585549294","title":"九洲药业(603456.SH)：甲苯磺酸艾多沙班化学原料药上市申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2585549294","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585549294?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:15","pubTimestamp":1763972158,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九洲药业(603456.SH)公告，公司收到国家药品监督管理局颁发的关于甲苯磺酸艾多沙班的《化学原料药上市申请批准通知书》。甲苯磺酸艾多沙班是一种口服抗凝药物，主要用于预防非瓣膜性房颤患者的卒中及全身性栓塞，以及治疗或预防深静脉血栓和肺栓塞。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"九洲药业(603456.SH)：甲苯磺酸艾多沙班化学原料药上市申请获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0070","603456"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776250571410,"stockEarnings":[{"period":"1week","weight":0.0249},{"period":"1month","weight":0.0262},{"period":"3month","weight":-0.1198},{"period":"6month","weight":-0.1274},{"period":"1year","weight":0.3962},{"period":"ytd","weight":-0.0358}],"compareEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":-0.0168},{"period":"3month","weight":-0.0241},{"period":"6month","weight":0.0282},{"period":"1year","weight":0.2341},{"period":"ytd","weight":0.0146}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江九洲药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"59157人(较上一季度增加10.22%)","perCapita":"15035股","listingDate":"2014-10-10","address":"浙江省台州市椒江区外沙路99号","registeredCapital":"88944万元","survey":" 浙江九洲药业股份有限公司的主营业务是为全球制药公司、生物科技公司、科研机构等提供一站式的医药定制研发和生产（CDMO）服务。公司的主要产品是抗感染类、中枢神经类药物、非甾体类药物、降血糖类药等。公司荣获2025中国医药CDMO企业20强、2024年度中国医药工业主营业务收入前100位企业、2024年EcoVadis企业社会责任评级“金牌”认证、全球优选合作伙伴奖、ESG责任企业奖等多项荣誉。","listedPrice":15.43},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"九洲药业(603456)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供九洲药业(603456)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"九洲药业,603456,九洲药业股票,九洲药业股票老虎,九洲药业股票老虎国际,九洲药业行情,九洲药业股票行情,九洲药业股价,九洲药业股市,九洲药业股票价格,九洲药业股票交易,九洲药业股票购买,九洲药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"九洲药业(603456)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供九洲药业(603456)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}